![Insights from 2024 ASCO® GU Annual Meeting](http://media.vumedi.com/thumbs/channel_logo/2024/1/a56c8c4b-9ce6-43ad-840c-b4fc2e23cbdf.png.200x0_q85.png)
Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Insights: "EMBARK Trial - Outcomes of Men With High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment"
By
Insights from 2024 ASCO® GU Annual Meeting
FEATURING
Neal Shore
By
Insights from 2024 ASCO® GU Annual Meeting
FEATURING
Neal Shore
268 views
February 20, 2024
Comments 0
Login to view comments.
Click here to Login
Videos